Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glutamate Changes as a New Neurocognitive Marker in Psychosis

NCT07196423 is registered in ClinicalTrials.gov with University of Nottingham as lead sponsor.

NCT NCT07196423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07196423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glutamate Changes as a New Neurocognitive Marker in Psychosis
Lead sponsor
University of Nottingham
Phase
Not applicable
Overall status
Recruiting
Start date
February 9, 2026
Completion date
August 31, 2027
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first episode psychosis (fep), psychosis